1. Toward the Design of Allosteric Effectors: Gaining Comprehensive Control of Drug Properties and Actions.
- Author
-
Tee WV, Lim SJM, and Berezovsky IN
- Subjects
- Allosteric Regulation drug effects, Humans, Ligands, SARS-CoV-2 drug effects, Proto-Oncogene Proteins p21(ras) antagonists & inhibitors, Proto-Oncogene Proteins p21(ras) metabolism, Proto-Oncogene Proteins p21(ras) chemistry, Binding Sites, Drug Design, Allosteric Site
- Abstract
While the therapeutic potential of allosteric drugs is increasingly realized, the discovery of effectors is largely incidental. The rational design of allosteric effectors requires new state-of-the-art approaches to account for the distinct characteristics of allosteric ligands and their modes of action. We present a broadly applicable computational framework for obtaining allosteric site-effector pairs, providing targeted, highly specific, and tunable regulation to any functional site. We validated the framework using the main protease from SARS-CoV-2 and the K-Ras
G12D oncoprotein. High-throughput per-residue quantification of the energetics of allosteric signaling and effector binding revealed known drugs capable of inducing the required modulation upon binding. Starting from fragments of known well-characterized drugs, allosteric effectors and binding sites were designed and optimized simultaneously to achieve targeted and specific signaling to distinct functional sites, such as, for example, the switch regions of K-RasG12D . The generic framework proposed in this work will be instrumental in developing allosteric therapies aligned with a precision medicine approach.- Published
- 2024
- Full Text
- View/download PDF